Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...

The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...

The global breast cancer therapeutics market is expected to grow from US$ 31.07 billion in 2022 to US$ 63.9 billion by 2030, ...

Pfizer has revealed that its much-anticipated selective oestrogen receptor degrader (SERD) vepdegestrant for breast cancer missed the mark for a key endpoint in its first phase 3 trial readout.

Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and ...

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor ...

Pfizer (NYSE:PFE) is currently dealing with shareholder proposals concerning governance issues such as religious ...

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

At the Tandem Meetings 2025, researchers presented a study of scalp cooling in patients undergoing chemotherapy and ASCT.

Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...